Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC.
Introduction
Hepatocellular carcinoma (HCC) is the third major cause of cancer-related deaths in the world and the second most leading cancer for mortality in China (1, 2) . Despite the improvement in the survival rate of HCC patients with available treatment such as surgery, chemotherapy and biologics, most HCC patients still encounter a poor prognosis with a >60% recurrence rate within 5 years after resection due to high metastasis frequency (3, 4) . Therefore, it is important to search for vital molecular markers and mechanisms underlying HCC initiation and progression. There is always a demand to elucidate key driven events in HCC development and to further identify valuable factors for the prognosis prediction and novel therapeutic strategies for HCC.
Altered energy metabolism is proving to be an important differentiating feature of cancer cells, which has been regarded as one of the hallmarks of cancers (5) . In mammalian cells, there are two major ways to maintain glucose homeostasis; the catabolic glycolysis/oxidative phosphorylation pathway and the anabolic gluconeogenesis pathway. In normal cells, glucose is first converted to pyruvate in the cytoplasm in the presence of oxygen; pyruvate is then channeled to the tricarboxylic acid cycle for maximal ATP synthesis in the mitochondria (6) . However, in cancer cells, even in the presence of oxygen, pyruvate is preferentially converted to lactate, which is known as the Warburg effect (aerobic glycolysis) (7) . However, molecular mechanisms underlying the Warburg effect remain unclear. Fructose-1, 6-bisphosphatase 1 (FBP1), a pivotal gluconeogenesis regulatory enzyme, catalyzes the hydrolysis of fructose 1, 6-bisphosphate to fructose 6-phosphate and inorganic phosphate. FBP1 is one of the two isoenzymes of FBP in mammalian cells, which is ubiquitously expressed in different tissues while another paralog FBP2 is restricted to only muscle tissues (8) .
Recently, accumulating evidences disclosed the role of FBP1 in the development and progression of some cancer types, such as renal carcinoma (9) , breast cancer (10), gastric cancer (11) , lung cancer (12) and pancreatic adenocarcinoma (13) , it has been hypothesized to act as a tumor suppressor, including in HCC (14) . However, functional researches of FBP1 in the development and progression of HCC remain yet to be explored.
In this study, we found that FBP1 was downregulated in HCC, which indicated a poor prognosis. Also, we investigated the effect of FBP1 on cell proliferation and metastasis, and further explored the role of FBP1 in suppressing HCC progression by depressing the Warburg effect.
Materials and methods

Clinical sample and immunohistochemistry staining
Tumor specimens used in tissue microarray analysis were derived from HCC patients who underwent curative resection at the Eastern Hepatobiliary Surgery Hospital (EHBH) between 1996 and 2001; patients in the prognostic group were monitored every 2-3 months during the first year until October 2010 giving a median follow-up range of 0.3-141 months. No patients in this study received pre-operative anticancer treatment. The inclusion and exclusion criteria of patients used in this study was reported previously (15) . The overall survival rate was defined as the length of time between surgery and death or between surgery and the last observation point. The time of recurrence was defined as the length of time between the date of surgery and the date of any diagnosed relapse.
For the use of clinical materials for research purpose, prior patients' consents and approval were obtained from the Ethics Committee of Renji Hospital, Shanghai Jiao Tong University School of Medicine and EHBH of the Second Military Medical University. All experiments were performed in accordance with approved guidelines of Shanghai Jiao Tong University School of Medicine.
Immunohistochemical staining for FBP1 was done as previously described (16) . Antibody detecting FBP1 (HPA005857) was purchased from Sigma (1:2000) . Immunohistochemical score was independently assessed by two pathologists without knowledge of patient characteristics.
Cell culture
Human normal liver cell line L02 was obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Human HCC cells (HepG2, Hep3B, SK-Hep1) were purchased from the American Type Culture Collection. Human HCC cells (SMMC7721, MHCC97H and HCCLM3) were provided by the Liver Cancer Institute of Zhongshan Hospital, Fudan University (Shanghai, China). Huh7 cells were purchased from Riken Cell Bank (Tsukuba, Japan). All of the cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 μg/ml penicillin and 100 μg/ml streptomycin and stored at 37°C in a 5% CO 2 incubator. The identities of the cell lines were confirmed by STR testing in 2014.
Lentivirus production and stable cell lines
Lentivirus was produced in HEK293T cells by cotransfection of pWPXL, pWPXL-FBP1, shFBP1#1, shFBP1#2 or shFBP1#3 with packaging plasmid psPAX2 and enveloped plasmid pMD2.G (Addgene) using Lipofectamine 2000 (Invitrogen).Viruses were harvested at 48 h after transfection, and the viral titers were determined with lentiviral titer by limiting dilution. Firstly, 293T cells (1 × 10 5 ) were seeded onto 12-well plate in 1000 μl of DMEM medium with 10% fetal bovine serum and 6 μg/ml polybrene and incubated at 37°C for 1 h, then the original lentiviral fluid with different concentration gradients of 0.1, 0.5 and 2 μl was, respectively, added to the cells. After 72 h, the GFP expression was measured by fluorescenceactivated cell sorting. 
RNA isolation and real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen) and reversely transcribed using the Prime-Script™ RT Reagent Kit (TaKaRa Biotechnology). Real-time polymerase chain reaction (real-time PCR) was subsequently performed according to the manufacturer's instructions (TaKaRa Biotechnology). Expression levels were normalized against β-actin, and the relative expression levels were displayed using 2 −ΔΔCt method and the calculation equation is 2 −ΔΔCt (ΔCt = ΔCt target − ΔCt β-actin ) (17) . The primer sequences used were as follows: FBP1: Forward: ACATCGATTGCCTTGTGTCC;
Reverse: CATGAAGCAGTTGACCCCAC; β-actin: Forward: TTGTTACAGGAAGTCCCTTGCC; Reverse: ATGCTATCACC TCCCCTGTGTG.
Western blot analysis
Briefly, total protein of HCC tissue samples and HCC lines was extracted using protein extraction reagent (Thermo Scientific) with a cocktail of proteinase inhibitors (Roche Applied Science, Switzerland) and a cocktail of phosphatase inhibitors (Roche Applied Science) according to the manufacturer's protocol. Equal amounts of total proteins (20 μg) were separated by 10% SDS-PAGE and transferred onto a polyvinylidene difluoride membrane using a BioRad SemiDry apparatus. After blocking for non-specific binding, the membranes were incubated with anti-FBP1 (1:300 dilution; Sigma) or β-actin (1:10 000 dilution; Sigma) overnight at 4°C and followed by an incubation period of 1 h at room temperature with secondary antibody (1:4000, Bioword). Bands were detected by a Bio-Rad ChemiDoc XRS system, and quantification was analyzed using Image Lab software.
In vitro cell behavior assays
Transwell filter chambers (BD Biosciences) and transwells coated with Matrigel (BD Biosciences) were used to evaluate the migration and invasion of HCC cells. Cells were seeded onto the upper chambers in 200 μl serum-free DMEM media while 600 μl media were supplemented with 10% fetal bovine serum onto the lower chambers. 5 × 10 4 SK-Hep1, 8 × 10 4 HepG2 and 8 × 10 4 Huh7 cells were seeded on the upper chambers. For the migration assay, these three cell lines were incubated at 37°C for 12 h. For the invasion assay, which were incubated at 37°C for 24 h. Then, the wells were washed with phosphate-buffered saline and the cells adhering to the lower side were fixed and stained with Crystal violet (1% in methanol) for 10 min; after which they were visualized and photographed with a CKX41 microscope (Olympus, Japan) at 200× magnification. Images
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fructose-1, 6-bisphosphatase 1 HCC hepatocellular carcinoma of three random fields from three replicate wells were obtained, and the migrated or invasive cells were counted. For the cell proliferation assay, cells (1 × 10 3 ) were seeded in 100 μl of complete culture media in 96-well microplates for various time periods. Cell Counting Kit-8 assay (Dojindo Laboratories, Kumamoto, Japan) was performed to measure cell viability according to manufacturer's instructions. For colony formation assays, 1000 cells (HepG2-FBP1, SK-Hep1-FBP1, Huh7-shFBP1 and their relative mock cells) were plated onto six-well plates and incubated at 37°C for ~2 weeks. When the cells grew to visible colonies, the cells were washed twice with phosphate-buffered saline and fixed in 4% paraformaldehyde for 30 min. Then, cells were stained with crystal violet, and the numbers of the colonies were counted per well.
Xenograft model
Mice were manipulated and housed according to protocols approved by Shanghai Medical Experimental Animal Care Commission. For in vivo tumor formation, 5 × 10 6 HepG2 cells stably expressing FBP1 were suspended in 200 μl serum-free DMEM and subcutaneously injected into the right flank of each mouse, while the vector control cells were injected into the left flank. The volumes of the tumors were measured after 6 weeks and the mice were sacrificed. For pulmonary metastasis, 2 × 10 5 HepG2 cells were injected into tail vein of nude mice. After 6 weeks, all the mice were sacrificed. The lung tissues were dissected and fixed with 4% formalin for at least 72 h. Lung tissues were examined by hematoxylin and eosin (H & E) staining.
Measurements of lactate production and ECAR
Lactate production was detected by the colorimetric lactate assay kit (Bio Vision) according to the manufacturer's instructions. HCC cells with FBP1 overexpression or knockdown were incubated in lactate assay buffer containing enzyme and lactate probes. Then, optical density was measured at 570 nm.
Extracellular acidification rates (ECAR) were measured using a Seahorse XF24 analyzer (Seahorse Biosciences). The assay workflow is as follows. First, cells are incubated in the glycolysis stress test medium without glucose or pyruvate. The first injection is a saturating concentration of glucose. The cells utilize the glucose injection and catabolize it though the glycolytic pathway to pyruvate, producing ATP, NADH, water and protons. The extrusion of protons into the surrounding medium causes a rapid increased in ECAR. This glucose-induced response is reported as the rate of glycolysis under basal conditions. The second injection is oligomycin, which inhibits ATP synthase in the mitochondria resulting in an increased dependence on glycolysis. The final injection is 2-dexoy-glucose, a competitive inhibitor of glucose and functions to shut down glycolysis. More specifically, cells were planted at 8000 cells per well in a 96-well cell culture XF microplate (Seahorse Bioscience) and incubated overnight. Then, cells were washed with 37°C assay medium (unbuffered DMEM supplemented with 2 mM l-glutamine, pH 7.4) and thereafter the cell culture microplate was placed into a 37°C non-CO 2 incubator for 1 h prior to assay. The cartridge ports A, B, C were, respectively, loaded with 25 μl glucose (80 mM), oligomycin (9 μM) and 2-dexoy-glucose (1 M). Each drug concentration was optimized on cell lines prior to assay. All measurements were normalized to cell number using the crystal violet assay. ECAR after glucose treatment indicates glycolysis rate. ECAR after oligomycin treatment indicates glycolysis capacity.
Statistical analysis
Data were presented as the mean ± SEM. The statistical analysis and graphical presentation were performed with GraphPad Prism 5.0. Quantitative variables were analyzed with Student's t tests. P< 0.05 was considered significant. Kaplan-Meier analysis was used to assess survival.
Results
FBP1 expression is frequently downregulated in human HCC
We first assessed the expression of FBP1 in human HCC tissues. The Oncomine platform can be used for analysis and visualization in searching for clinically important annotation to facilitate the discovery of the novel biomarkers and therapeutic targets (18) . Besides, Differential expression analyses from Oncomine microarray gene datasets comparing most major types of cancer with respective normal tissues as well as a variety of cancer of cancer subtypes are available for exploration (19) . As shown in the public datasets on Oncomine (www.oncomine.org), FBP1 downregulation was observed in most of the tumor types, including liver cancer, kidney cancer, lung cancer, etc. In liver cancer datasets, we found that mRNA levels of FBP1 were significantly decreased in HCC tissues compared to normal liver tissue in the Roessler 2 dataset, the Wurmbach dataset, the Chen dataset and the Roessler dataset (Supplementary Figure 1A- D, available at Carcinogenesis Online). Subsequently, expression levels of FBP1 in tumor and peritumoral tissues of HCC were analyzed. As shown in Figure 1A and B, mRNA levels of FBP1 were significantly downregulated in HCC tissues compared to peritumoral tissues in 69 patients. Downregulation of FBP1 was also validated by western blotting ( Figure 1C ). Cancer Genome Atlas (TCGA) dataset also showed that expression levels of FBP1 in HCC tissues were significantly lower than that in peritumoral tissues ( Figure 1D ).
Downregulation of FBP1 predicts poor prognosis of patients with HCC
To investigate prognostic significance of FBP1 in HCC, tissue microarray analysis of HCC tissues from 224 patients who underwent liver resection was carried out. Representative immunostaining results of FBP1 were shown in Figure 2A . All the HCC patients were divided into two groups: FBP1 positive group (n = 167) and FBP1 negative group (n = 57). We found that patients with positive FBP1 expression exhibited a much higher overall survival rate and had a lower tendency of disease recurrence ( Figure 2B ). To further confirm clinical significance of FBP1 in HCC, we used the FBP1 expression levels in HCC patients from the TCGA data. Results showed that FBP1 expression was lower in HCC patients with vascular cell invasion (n = 106, P = 0.0052, Figure 2C ) and a high pathological grade (Stages III-IV) (n = 88, P = 0.0185, Figure 2D ). More importantly, HCC patients with higher levels of FBP1 had better overall survival rates (P = 0.0072, Figure 2E ), which is consistent with the results from our cohort. Therefore, these data suggest that FBP1 may serve as a valuable factor for predicting the prognosis of HCC patients.
Knockdown of FBP1 enhances the colony formation, proliferation and metastasis of HCC cells in vitro
To investigate the function of FBP1 in HCC, we observed expression levels of FBP1 in a normal liver cell line L02 and seven HCC cell lines, including HepG2, SMMC7721, Huh7, SK-Hep1, HCCLM3, MHCC97H and Hep3B. Results showed that FBP1 expression was notably deceased in HCC cell lines compared to the normal cell line L02, which was determined by both qRT-PCR and western blot analysis ( Figure 3A and B) . Huh7 cells, which expressed relatively higher level of FBP1 among the HCC cell lines, were infected with lentivirus-mediated FBP1 shRNAs (shFBP1#1, shFBP1#2, shFBP1#3). Knockdown efficiency was confirmed by both qRT-PCR and western blotting analyses ( Figure 3C and D) . We noted that proliferation of Huh7 cells was significantly increased after FBP1 knockdown ( Figure 3E ). Colony formation assays also showed that silencing endogenous FBP1 in Huh7 cells significantly enhanced the ability of colony formation ( Figure 3F ). Furthermore, decreased expression of FBP1 significantly enhanced cell migration and invasion in Huh7 cells ( Figure 3G ).
FBP1 overexpression inhibits the colony formation, proliferation and metastasis of HCC cells in vitro and in vivo
To further confirm effects of FBP1 on colony formation, proliferation and metastasis, FBP1 was overexpressed in HepG2 and SK-Hep1 cells which had relatively lower levels of FBP1. Efficiency of overexpression was confirmed by both qRT-PCR and western blotting analyses ( Figure 4A ). As indicated in Figure 4B and C, in colony formation and CCK8 assays, the abilities of colony formation and cell proliferation were significantly suppressed in HepG2 and SK-Hep1 cells with FBP1 overexpression. Furthermore, migratory and invasive abilities of HCC cells were obviously attenuated after overexpression of FBP1 ( Figure 4D ). In order to explore the effect of FBP1 on proliferation and metastasis of HCC cells in vivo, we established two xenograft models. First, we subcutaneously transplanted HepG2-vector or HepG2-FBP1 cells into nude mice. Immunohistochemical staining confirmed that FBP1 expression was increased in tumor tissues formed by HepG2-FBP1 cells in comparison with tumor tissue developed from HepG2-vector cells. In addition, the sizes of tumors formed by HepG2-FBP1 cells were significantly decreased compared with those developed from HepG2-Vector cells ( Figure 4E ). Then, we established tail vein injected models to further verify the role of FBP1 in HCC metastasis. The micrometastatic lesions were histologically examined and microscopically detected. Results showed that HepG2-FBP1 cells caused significant decreased numbers of lung metastatic nodules than control cells ( Figure 4F) . The above results indicate that FBP1 may play a role in hepatocarcinogenesis.
FBP1 suppresses the Warburg effect by depressing glycolysis in HCC
The Warburg effect (or aerobic glycolysis) is a well-characterized metabolic alteration that ubiquitously occurs in neoplastic cells and characterized by a surprisingly high rate of lactate production instead of carbon dioxide as the final metabolite (20) .
To investigate the effect of FBP1 on the Warburg effect, levels of lactate production and glycolytic rates were detected in HCC cell lines. Production of lactate in the culture media was pronouncedly decreased in HepG2 and SK-Hep1 cells after FBP1 overexpression ( Figure 5A ). On the contrary, a much higher level of lactate was observed in Huh7 cells after silencing of FBP1 ( Figure 5B ). To further evaluate the impact of FBP1 on HCC glycolysis, ECAR were detected with the XF24 Extracellular Flux analyzer (Seahorse). ECAR means glycolysis rate after glucose treatments and ECAR is equal to glycolysis capacity after oligomycin treatment. Results showed that overexpression of FBP1 significantly reduced the rate of glycolysis and glycolytic capacity of HepG2 and SK-Hep1 cells ( Figure 5C ), while knockdown of FBP1 significantly elevated both ( Figure 5D ).
Inhibition of the Warburg effect by FX11 results in decreased cell proliferation and metastasis in HCC cells
Since FBP1 exhibits a suppressive role in HCC cell proliferation, metastasis and the Warburg effect, it can be postulated that FBP1-mediated functions in HCC may be associated with the Warburg effect. FX11 [3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid], a small-molecule inhibitor that targets LDHA, inhibits glycolysis and alters cellular energy metabolism (21) . To further investigate whether the Warburg effect was responsible for aggressiveness of HCC cells, HepG2-Vector and Huh7-shFBP1#2 cells were treated with FX11 at different concentrations of 1, 5 and 10 μM for 24 h. Results showed that FX11 significantly inhibited glycolysis in a dosedependent manner in HepG2-Vector and Huh7-shFBP1#2 cells ( Figure 6A ). Subsequently, proliferation and migration of HCC cells were analyzed in FX11-treated cells to assess the effects of glycolysis inhibition. CCK8 assays revealed that proliferation of HepG2-Vector and Huh7-shFBP1#2 cells was suppressed by FX11 in a dose-dependent manner ( Figure 6B) . Notably, abilities of cell migration and invasion also decreased in a dose-dependent manner in HepG2-Vector and Huh7-shFBP1#2 cells ( Figure 6C ). These data indicate that downregulation of FBP1 facilitates glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells.
Discussion
Although enormous advances have been achieved in HCC diagnosis and therapy, poor quality of prognosis has not been changed substantially. Therefore, identifying molecular mechanism of HCC progression and searching for valuable prognostic predictors that would effectively improve the poor outcomes of HCC is extremely important. In this study, we found FBP1 was downregulated in HCC tissues and cells, which contributed to tumor progression and poor prognosis, providing supportive evidence for studies published recently which showed that the downregulation of FBP1 was correlated with an unfavorable prognosis of HCC patients in three independent cohorts containing 594 cases of HCC (14) . In addition, Chen et al. (22) have reported the prognostic value of FBP1 expression in HCC patients indicates that FBP1 could be a potential predictive marker for the prognosis of HCC patients. Our tissue microarray analysis results of immunohistochemical staining of HCC tissues as well as TCGA dataset both revealed that FBP1 deficiency predicted a poor overall survival rate, which indicated that FBP1 may be regarded as a potential prognosis biomarker in HCC. In many reports, mechanisms involved in FBP1 repression in tumors were suggested to be associated with DNA methylation of the FBP1 promoter. NF-kappaB functioned downstream of Ras to promote DNA methylation of FBP1 promoter, which was used as an independent prognosis predicator for gastric cancer (11). Dong et al. (10) also reported that the Snail-G9a-Dnmt1 complex was required for the methylation of the FBP1 promoter in basal-like breast cancer. In lung cancer, FBP1 was downregulated via the binding of Zinc figure E-box-binding homeobox1 (ZEB1) to the FBP1 promoter to enhance DNA methylation (12) . Additionally, epigenetical silencing mechanism of histone modification may play an important role in FBP1 downregulation. It has been reported that the knockdown or pharmacological inhibition of histone demethylase LSD1 notably activates the transcription of FBP1 and G6Pase in liver cancer cells (23) . However, another report has shown that FBP1 is inactivated by promoter methylation in human liver and colon cancer cell lines (24) . Further studies are needed to clarify the genetic and epigenetic mechanism involved in FBP1 regulation, as well as other modulators which could affect FBP1 activity in HCC.
The role of FBP1 in carcinogenesis of solid tumors has been described in several studies in which FBP1 is established as a tumor suppressor. FBP1 was reported to be poorly expressed in lung cancer tissues and cells (25) . Restoration of FBP1 expression reduced growth, invasion and glycolysis in lung cancer cells (12) . FBP1 was also downregulated in gastric carcinomas and gastric cancer cells. Restoration of FBP1 antagonized glycolysis and suppressed growth in gastric cancer cells (11) . In breast cancer, loss of FBP1-mediated metabolic reprogramming resulted in an increased cancer stem cell-like property and tumorigenicity by enhancing the interaction of β-catenin with T-cell factor (10). Hirata et al. (14) recently reported in conditions expressing low levels of FBP1, promoting tumor growth and intracellular uptake of glucose via altering glucose metabolism. However, there is less evidence provided for the functional studies of FBP1 in HCC progression. In our study, in vitro and in vivo studies showed that overexpression of FBP1 significantly decreased the proliferation and metastasis of HCC cells. Conversely, silencing of FBP1 was found to promote cell growth, migration and invasion in vitro. It should be taken into consideration that whether an altered growth rate will affect the results obtained for migration and invasion. However, within the first 48 h, no effect could be seen on the rate of cell growth. Therefore, we can conclude that the rate of cell growth remained constant and did not affect the ability of cell migration and invasion. To the best of our knowledge, this is the first report that FBP1 expression is significant for metastasis of HCC, as well as its important role in tumor proliferation and growth of human HCC. In addition, we also reveal that FBP1 plays a suppressive role in aerobic glycolysis by reducing lactate production and glycolytic rates (as shown in Figure 5 ). Therefore, we suggest that whether there is an association between FBP1 and the Warburg effect in HCC.
Recently, a functional rationale for aerobic glycolysis in cancer cells has been elucidated. Aerobic glycolysis provides invasion of Huh7 cells transfected with shFBP1 were detected by trans-well migration and matrigel invasion assays (magnification, ×200). Date shown are mean ± SEM of three independent experiments (*P < 0.05, **P < 0.01). P values were calculated using Student's t-test.
a constant supply of metabolites that are essential for rapid macromolecule biosynthesis and necessary for cell growth and division, promoting the rapid proliferation of tumor cells (26) . Additionally, aerobic glycolysis is considered to be a key driver for tumor metastasis and therapeutic resistance (27) . Further studies revealed that FBP1 exerted its tumor-suppressive roles by inhibiting the Warburg effect in our study. It is known that the Warburg effect itself involves high levels of aerobic by transwell migration and matrigel invasion assays after FBP1 overexpression (magnification, ×200). Data shown is the mean ± SEM of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001). P values were calculated using Student's t-test. (E) Left, immunohistochemical staining in tumors formed by FBP1-overexpressing (HepG2-FBP1, the right flank of each mouse) and control (HepG2-Vector, the left flank of each mouse) (magnification, ×400). Right, size of the xenograft tumors formed by FBP1-overexpressing (HepG2-FBP1) and control (HepG2-Vector) cells (*P < 0.05, **P < 0.01). (F) Representative lung tissue sections of H&E staining from each group (n = 8) of HepG2-Vector and HepG2-FBP1. Number of lung metastatic foci with tail vein injection was calculated 6 weeks after implantation (magnification, ×100, ×200) (***P < 0.001).
glycolysis catalyzed by pivotal enzymes that are therapeutically accessible to small drug-like inhibitors. The tetrameric LDH-A enzyme kinetically favors the conversion of pyruvate to lactate, a hallmark of the Warburg effect, and hence is a favorable therapeutic target and a vital point for glycolytic flux (28) . FX11, was reported as a small-molecule inhibitor targeting LDH-A, resulting in depressed glycolysis in some kinds of cancers (21, 28, 29) . In this study, FX11 could not only dramatically inhibit basal aerobic glycolysis in HepG2-vector cells, but also block the increased aerobic glycolysis by FBP1 knockdown in Huh7-shFBP1 cells ( Figure 6A) ; further studies revealed that FX11 could also decrease the proliferation and metastasis of HCC cells in a dose-dependent manner. These results confirm suppressive role of FBP1 in HCC progression by inhibiting the Warburg effect. Le et al. (21) reported that the inhibitory effect of tumor xenograft progression was mediated by inducing oxidative stress and ROSdependent cell death after treatment with FX11.
Li et al. (9) found that FBP1 restrained cell proliferation and glycolysis by inhibiting nuclear HIF-1α function via direct interaction with the HIF inhibitory domain. As a glycolysis antagonist, FBP1 deficiency would in turn cause an increase in aerobic glycolysis (as shown in Figure 5B and D) , the critical consequence of the Warburg effect is an increased lactate production and secretion, which would result in the acidification of the tumor microenvironment and a number of oncogenes and tumor suppressor genes are involved in the metabolic switch from oxidative phosphorylation toward aerobic glycolysis of tumor cells (30, 31) . The hypoxic and acidic tumor microenvironment favors the activation of a series of proteases associated with extracellular matrix degradation, angiogenesis and migration. Further research needs to confirm whether the function of FBP1 in affecting the metastasis of HCC is relevance to the altered proteases in HCC.
In conclusion, results obtained from both clinical specimens and HCC cells lines demonstrated that FBP1 expression is downregulated in HCC, and it has been unveiled that FBP1 exerts a suppressive role in HCC progression by negatively regulating the Warburg effect. These results provide evidence that FBP1 plays an important role in HCC and might be a potential marker for predicting the prognosis of HCC. 
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